Clinical Trials Logo

Hepatitis clinical trials

View clinical trials related to Hepatitis.

Filter by:

NCT ID: NCT02766933 Active, not recruiting - Hepatitis B Clinical Trials

Cameroon Baptist Convention Health Board Chronic Hepatitis B Cohort Study

Start date: May 2016
Phase:
Study type: Observational [Patient Registry]

The natural history and response to therapy of chronic hepatitis B infection in West Africa are currently poorly understood. In this study, employees of the Cameroon Baptist Convention Health Board (CBCHB) and spouses who are found to be hepatitis B positive on screening will be offered enrollment. Disease monitoring and treatment will be provided following current WHO guidelines. Clinical data will be prospectively recorded for 5 years, and bio-specimens will be frozen for future analysis.

NCT ID: NCT02765802 Completed - Clinical trials for Hepatitis D, Chronic

A Study to Evaluate Pegylated Interferon Lambda Monotherapy in Patients With Chronic Hepatitis Delta Virus Infection

LIMT
Start date: October 19, 2016
Phase: Phase 2
Study type: Interventional

To evaluate safety and tolerability of lambda over a 48-week treatment period in HDV patients.

NCT ID: NCT02765490 Completed - Clinical trials for Hepatitis C, Chronic

Efficacy and Safety of Combinations of AL-335, Odalasvir (ODV) and Simeprevir (SMV) in the Treatment of Chronic Hepatitis C Infection

Start date: November 9, 2016
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy (proportion of subjects with SVR12), safety, tolerability and pharmacokinetics of an 8- and 6-week treatment regimen of AL-335, odalasvir (ODV) and simeprevir (SMV) in chronic HCV genotype 1, 2, 4, 5 or 6 infected subjects without cirrhosis.

NCT ID: NCT02764671 Recruiting - Hepatitis B Clinical Trials

Safety and Immunogenicity of Recombinant Hepatitis B Vaccines in the Neonates

Start date: May 2015
Phase: Phase 4
Study type: Interventional

The purpose of this study is to further evaluate the immunogenicity and safety of 10μg/0.5ml Recombinant Hepatitis B Vaccines(Saccharomyces Cerevisiae) in the Healthy Neonates.

NCT ID: NCT02761629 Completed - Clinical trials for Hepatitis C, Chronic

Efficacy and Safety of Peg-Interferon Alpha-2a Plus Ribavirin in Genotype 1 Chronic Hepatitis C Participants Co-Infected With Human Immunodeficiency Virus

Start date: April 2006
Phase: Phase 4
Study type: Interventional

This randomized, multi-center, Phase IV, comparative study will assess the efficacy and safety of combined peg-interferon alpha-2a (Peg-IFN-Alpha-2A) and ribavirin therapy for 48 or 72 weeks of treatment and 24 weeks of follow-up in participants with Genotype 1 chronic hepatitis C (CHC), co-infected with human immunodeficiency virus type 1 (HIV-1).

NCT ID: NCT02760758 Completed - Hepatitis C Clinical Trials

A Study of CDI-31244: A Novel NNI in HV and HCV Infected Subjects

Start date: April 2016
Phase: Phase 1
Study type: Interventional

This is a First in Human study of orally administered CDI-31244, a non-nucleoside inhibitor (NNI) in healthy volunteers and HCV infected individuals

NCT ID: NCT02760355 Completed - Insulin Resistance Clinical Trials

Extrahepatic Insulin Resistance in Chronic Hepatitis C

Start date: March 2016
Phase: N/A
Study type: Interventional

In this pilot study, the investigators plan to treat patients with chronic hepatitis C due to HCV genotype 3 infection using an interferon-free regimen consisting in the administration of ribavirin and sofosbuvir/ledipasvir - a combination of a nucleotide RNA polymerase inhibitor with a non-structural protein 5A inhibitor. Patients will undergo a euglycemic hyperinsulinemic clamp, using tracers, and indirect calorimetry to assess whether the viral suppression induced by this regimen will be capable of reversing the glucose metabolic alterations induced by HCV in both the liver and extrahepatic compartments. Adipose and muscle tissue biopsies will also be performed to assess some specific molecular changes induced by HCV.

NCT ID: NCT02759991 Completed - Clinical trials for Hepatitis E Infection

Effectiveness Trial to Evaluate Protection of Pregnant Women by Hepatitis E Vaccine in Bangladesh.

Start date: October 2, 2017
Phase: Phase 4
Study type: Interventional

The aim of the study is to determine the effectiveness of hepatitis E virus vaccine given in women of child bearing age in preventing HEV disease during pregnancy among women in rural Bangladesh.

NCT ID: NCT02759861 Completed - Clinical trials for Genotype 1 Hepatitis C Virus

Determine the Efficacy and Safety of Harvoni in Genotype 1 Chronic Hepatitis c Infected People Who Are Alcoholics

Start date: August 1, 2016
Phase: Phase 4
Study type: Interventional

To determine the efficacy and safety of Harvoni in treatment-naïve alcoholic subjects with Genotype 1 HCV infection

NCT ID: NCT02759354 Completed - Hepatitis B Clinical Trials

Long-term Persistence of Hepatitis B and Pertussis Antibody Responses in Healthy 4 to 5 Year Old Children Previously Vaccinated With Vaxelis® or INFANRIX® Hexa (V419-012)

Start date: April 26, 2016
Phase: Phase 3
Study type: Interventional

This is a multicenter extension study of two European randomized, double-blind studies (V419-007 and V419-008). It describes long-term persistence of hepatitis B and pertussis antibody responses in healthy 4- to 5 year old children previously vaccinated with Vaxelis® or INFANRIX® hexa